Stock Research: RVL Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

RVL Pharmaceuticals

NasdaqGS:OSMT IE00BF2HDL56
6
  • Value
    6
  • Growth
    55
  • Safety
    Safety
    86
  • Combined
    16
  • Sentiment
    5
  • 360° View
    360° View
    6
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

RVL Pharmaceuticals plc is a pharmaceutical company focused on eye care and medical aesthetics products. It operates in the pharmaceutical industry, developing and commercializing products for ocular medicine and medical aesthetics, including Upneeq for acquired blepharoptosis and Arbaclofen ER for spasticity in multiple sclerosis patients. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC. In the last fiscal year, the company had a market cap of $0 million, profits of $40 million, revenue of $50 million, and 125 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 6 (better than 6% compared with alternatives), overall professional sentiment and financial characteristics for the stock RVL Pharmaceuticals are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for RVL Pharmaceuticals. The consolidated Value Rank has an attractive rank of 86, which means that the share price of RVL Pharmaceuticals is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 86% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 55, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 5. Professional investors are more confident in 95% other stocks. Worryingly, the company has risky financing, with a Safety rank of 6. This means 94% of comparable companies have a safer financing structure than RVL Pharmaceuticals. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
86 86 90 57
Growth
55 21 27 65
Safety
Safety
6 4 4 4
Sentiment
5 5 6 50
360° View
360° View
6 6 4 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
45 45 45 73
Opinions Change
50 50 50 50
Pro Holdings
n/a 18 12 63
Market Pulse
13 13 1 16
Sentiment
5 5 6 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
86 86 90 57
Growth
55 21 27 65
Safety Safety
6 4 4 4
Combined
16 16 24 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
32 32 32 32
Price vs. Earnings (P/E)
100 100 100 68
Price vs. Book (P/B)
86 86 89 66
Dividend Yield
1 1 1 1
Value
86 86 90 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
98 100 95 99
Profit Growth
36 36 36 35
Capital Growth
1 4 11 81
Stock Returns
47 1 1 9
Growth
55 21 27 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
34 27 26 19
Refinancing
1 1 1 1
Liquidity
13 13 13 51
Safety Safety
6 4 4 4

Similar Stocks

Discover high‑ranked alternatives to RVL Pharmaceuticals and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.